Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Bristol-Myers Squibb.

Online! Live Medical Crossfire®: Evaluating Immuno-Oncology Strategies Across Tumor Types

Release Date: January 31, 2019
Expiration Date: January 31, 2020
Media: Internet - based

Activity Overview

Immune checkpoint inhibitors represent an entirely new treatment modality in the fight against cancer. These therapies, which harness the body’s own immune system to eradicate tumor cells, are transforming outcomes across an increasingly broad range of malignancies and making long-term survival a reality where, until recently, prognoses were poor.

In order to help you gain a better understanding of the mechanisms of action of these new therapies, and remain apprised of emerging evidence across tumor types so that you can appropriately integrate these agents into the management of your patients and improve outcomes, we have developed a dynamic Medical Crossfire® program. In this activity, leading clinical experts in melanoma, lung cancer, and genitourinary malignancies share their perspectives on the latest data and factors that may change your clinical practice. This exchange of ideas will explore the integration of immune checkpoint inhibitors into treatment algorithms for relevant malignancies, provide insights regarding the evolution of biomarkers for tailoring patient selection, and discuss the management of class-specific adverse events, giving you the opportunity to assess the opinions of multidisciplinary experts and optimize your approach to applying clinical evidence to real-world clinical scenarios.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Bristol-Myers Squibb.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is intended for medical oncologists, hematologists, and fellows who treat patients with cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe the changing role of immunotherapies for cancer management in the context of mechanistic characteristics and logical combination approaches
  • Relate findings from clinical trials with immunotherapies across multiple lines of therapy and tumor types, as well as key ongoing clinical trials in the field
  • Recognize evolving roles for biomarkers in the context of applying immunotherapeutic approaches to the treatment of cancer
  • Describe appropriate management strategies for management and mitigation of both rarely and commonly encountered adverse events from immunotherapies

Faculty, Staff, and Planners' Disclosures


Toni K. Choueiri, MD
Director, Lank Center for Genitourinary Oncology
Director, Kidney Cancer Center
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: All money to institution: Pfizer, GSK, Novartis, BMS, Merck, Exelixis, Roche, AstraZeneca, Tracon, Peloton, Celldex, Foundation Medicine, Calithera, Takeda; Consultant: AstraZeneca, Alligent, Alexion, Sanofi/Aventis, Bayer, BMS, Cerulean, Eisai, Foundation Medicine, Exelixis, Genentech, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Ipsen, Up-to-Date, NCCN, Analysis Group; Speakers Bureau: AstraZeneca, Clovis, Janssen/ Johnson & Johnson, Roche/ Genentech, Tesaro Inc.

Jason J. Luke, MD, FACP
Assistant Professor of Medicine
The University of Chicago Medicine
Chicago, IL

Disclosures: Grant Research Support: AbbVie, Array, Boston Biomedical, Bristol-Myers Squibb, Celldex, CheckMate, Corvus, Delcath, Five Prime, Genentech, Immunocore, Incyte, MedImmune, MacroGenics, Novartis, Pharmacyclics, Palleon, Merck, Tesaro; Speakers Bureau: 7 Hills, Aduro, Actym, Alphamab Oncology, Amgen, Array, AstraZeneca, BeneVir, Bristol-Myers Squibb, Castle, CheckMate, Compugen, EMD Serono, Gilead, Ideaya, Janssen, Merck, NewLink, Novartis, RefleXion, Spring Bank, Syndax, Tempest, WntRx; Other: Array, AstraZeneca, BeneVir, Bristol-Myers Squibb, Castle, CheckMate, EMD Serono, Gilead, Ideaya, Janssen, Merck, NewLink, Novartis, RefleXion.

Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine
Chief, Division of Medical Oncology, Department of Medicine
Deputy Director, Albert Einstein Cancer Center
Bronx, NY

Disclosures: Grant Research Support: National Cancer Institute; Consultant: Glaxo, AstraZeneca, Clovis, Roche/Genentech, Boehringer Ingelheim, Lilly, Adgero; Shareholder: Adgero, Stelexis.

Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT

Disclosures: Grant Research Support: Agensys, AstraZeneca, Bayer, Clovis, Dendreon, Eli Lilly, Endocyte, Genentech, Innocrin, Johnson & Johnson, Lilly, MedImmune, Medivation, Merck, Millennium, Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi Aventis, Sotio; Consultant: Astellas, AstraZeneca, Bayer, Bellicum, Dendreon, Exelixis, Ferring, Johnson & Johnson, Lilly, Medivation, Millennium, Pfizer, Roche Laboratories, Sanofi, Aventis; Shareholder: Bellicum, Tyme

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By